Allosteric modulation of metabotropic glutamate receptors: Structural insights and therapeutic potential

Neuropharmacology

Volumn 60, Issue 1, 2011, Pages 66-81

  Gregory, Karen J ^a   Dong, Elizabeth N ^a   Meiler, Jens ^a,b   Conn, P Jeffrey ^a  

^a VANDERBILT UNIVERSITY MEDICAL CENTER   (United States)

^b VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Allosteric modulator; Chimeric receptors; G protein coupled receptors; Homology model; Neuromodulation; Site directed mutagenesis

Indexed keywords

2 [[(3,5 DICHLOROPHENYL)AMINO]CARBONYL]CYCLOHEXANECARBOXYLIC ACID; 2 METHYL 6 (2 PHENYLVINYL)PYRIDINE; 2 METHYL 6 (PHENYLETHYNYL)PYRIDINE; 3 [(2 METHYL 4 THIAZOLYL)ETHYNYL]PYRIDINE; 4 (1,1 DIMETHYLHEPTYL) 1',2',3',4',5',6' HEXAHYDRO 2,3' DIHYDROXY 6' (3 HYDROXYPROPYL)BIPHENYL; 4 CARBOXY 3 HYDROXYPHENYLGLYCINE; 6 METHYL 2 PHENYLAZO 3 PYRIDINOL; ADX 10059; AFQ 056; ANXIOLYTIC AGENT; BENZODIAZEPINE DERIVATIVE; BETA 2 ADRENERGIC RECEPTOR; BIPHENYL INDANONE A; CANNABINOID 1 RECEPTOR AGONIST; CINACALCET; FENOBAM; G PROTEIN COUPLED RECEPTOR; JNJ 16259685; MARAVIROC; MEMBRANE PROTEIN; METABOTROPIC RECEPTOR; METABOTROPIC RECEPTOR 2; METABOTROPIC RECEPTOR 4; METABOTROPIC RECEPTOR 5; METABOTROPIC RECEPTOR AGONIST; METABOTROPIC RECEPTOR ANTAGONIST; ORG 27569; RECEPTOR SUBTYPE; UNCLASSIFIED DRUG; UNINDEXED DRUG; VU 015541; VU 29;

AKINESIA; ALLOSTERISM; ANXIETY DISORDER; BINDING SITE; CATALEPSY; CHRONIC PAIN; CLINICAL TRIAL; COGNITIVE DEFECT; CRYSTAL STRUCTURE; DEPRESSION; DRUG DEPENDENCE; DRUG MECHANISM; DRUG RECEPTOR BINDING; DRUG SCREENING; DRUG STRUCTURE; DRUG TARGETING; DYSKINESIA; DYSTONIA; FRAGILE X SYNDROME; GASTROESOPHAGEAL REFLUX; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; HYPERPARATHYROIDISM; LIVER TOXICITY; MEMORY DISORDER; MENTAL DISEASE; MIGRAINE; MUTAGENESIS; NEUROLOGIC DISEASE; NEUROMODULATION; NONHUMAN; PARKINSON DISEASE; PHARMACOPHORE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DOMAIN; PROTEIN FUNCTION; PROTEIN STRUCTURE; PSYCHOSIS; QUANTITATIVE ANALYSIS; RECEPTOR BINDING; REVIEW; SCHIZOPHRENIA; SEIZURE; SLEEP DISORDER; STRUCTURAL HOMOLOGY; STRUCTURE ACTIVITY RELATION; UNSPECIFIED SIDE EFFECT; WITHDRAWAL SYNDROME;

ALLOSTERIC REGULATION; ALLOSTERIC SITE; PROTEIN BINDING; PROTEIN CONFORMATION; RECEPTORS, METABOTROPIC GLUTAMATE; STRUCTURE-ACTIVITY RELATIONSHIP;

EID: 78149495647     PISSN: 00283908     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.neuropharm.2010.07.007     Document Type: Review

References (217)

1. Addex Pharma ADX10059 Migraine Prevention Study. ClinicalTrials.gov [Internet] 2010, Available from:, National Library of Medicine (US), Bethesda (MD), NLM Identifier: NCT00820105, 2000 (cited 2010 Jun 23). http://clinicaltrials.gov/show/NCT00820105.
2. Alagarsamy S., Marino M.J., Rouse S.T., Gereau R.W.T., Heinemann S.F., Conn P.J. Activation of NMDA receptors reverses desensitization of mGlu5 in native and recombinant systems. Nat. Neurosci. 1999, 2:234-240.
3. Alagarsamy S., Saugstad J., Warren L., Mansuy I.M., Gereau R.W.T., Conn P.J. NMDA-induced potentiation of mGlu5 is mediated by activation of protein phosphatase 2B/calcineurin. Neuropharmacology 2005, 49(Suppl. 1):135-145.
4. Alexander G.M., Godwin D.W. Metabotropic glutamate receptors as a strategic target for the treatment of epilepsy. Epilepsy Res. 2006, 71:1-22.
5. Ametamey S.M., Treyer V., Streffer J., Wyss M.T., Schmidt M., Blagoev M., Hintermann S., Auberson Y., Gasparini F., Fischer U.C., Buck A. Human PET studies of metabotropic glutamate receptor subtype 5 with 11C-ABP688. J. Nucl. Med. 2007, 48(2):247-252.
6. Anderson J.J., Bradbury M.J., Giracello D.R., Chapman D.F., Holtz G., Roppe J., King C., Cosford N.D., Varney M.A. In vivo receptor occupancy of mGlu5 receptor antagonists using the novel radioligand [3H]3-methoxy-5-(pyridin-2-ylethynyl)pyridine). Eur. J. Pharmacol. 2003, 473:35-40.
7. Anderson J.J., Rao S.P., Rowe B., Giracello D.R., Holtz G., Chapman D.F., Tehrani L., Bradbury M.J., Cosford N.D., Varney M.A. [3H]Methoxymethyl-3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine binding to metabotropic glutamate receptor subtype 5 in rodent brain: in vitro and in vivo characterization. J. Pharmacol. Exp. Ther. 2002, 303:1044-1051.
8. Annoura H., Fukunaga A., Uesugi M., Tatsuoka T., Horikawa Y. A novel class of antagonists for metabotropic glutamate receptors, 7-(hydroxyimino)cyclopropa[b]chromen-1a-carboxylates. Bioorg. Med. Chem. Lett. 1996, 6:763-766.
9. Antony J., Kellershohn K., Mohr-Andra M., Kebig A., Prilla S., Muth M., Heller E., Disingrini T., Dallanoce C., Bertoni S., Schrobang J., Trankle C., Kostenis E., Christopoulos A., Holtje H.D., Barocelli E., De Amici M., Holzgrabe U., Mohr K. Dualsteric GPCR targeting: a novel route to binding and signaling pathway selectivity. FASEB J. 2009, 23:442-450.
10. Anwyl R. Metabotropic glutamate receptors: electrophysiological properties and role in plasticity. Brain Res. Brain Res. Rev. 1999, 29:83-120.
11. Attucci S., Carla V., Mannaioni G., Moroni F. Activation of type 5 metabotropic glutamate receptors enhances NMDA responses in mice cortical wedges. Br. J. Pharmacol. 2001, 132:799-806.
12. Awad H., Hubert G.W., Smith Y., Levey A.I., Conn P.J. Activation of metabotropic glutamate receptor 5 has direct excitatory effects and potentiates NMDA receptor currents in neurons of the subthalamic nucleus. J. Neurosci. 2000, 20:7871-7879.
13. Ayala J.E., Chen Y., Banko J.L., Sheffler D.J., Williams R., Telk A.N., Watson N.L., Xiang Z., Zhang Y., Jones P.J., Lindsley C.W., Olive M.F., Conn P.J. mGlu5 positive allosteric modulators facilitate both hippocampal LTP and LTD and enhance spatial learning. Neuropsychopharmacology 2009, 34:2057-2071.
14. Baldwin J.M., Schertler G.F., Unger V.M. An alpha-carbon template for the transmembrane helices in the rhodopsin family of G-protein-coupled receptors. J. Mol. Biol. 1997, 272:144-164.
15. Ballesteros J., Palczewski K. G protein-coupled receptor drug discovery: implications from the crystal structure of rhodopsin. Curr. Opin. Drug Discov. Devel. 2001, 4:561-574.
16. Ballesteros J., Weinstein H. Integrated methods for the construction of three dimensional models and computational probing of structure-function relations in G-protein coupled receptors. Methods Neurosci. 1995, 25:366-428.
17. Balschun D., Zuschratter W., Wetzel W. Allosteric enhancement of metabotropic glutamate receptor 5 function promotes spatial memory. Neuroscience 2006, 142:691-702.
18. Battaglia G., Busceti C.L., Molinaro G., Biagioni F., Traficante A., Nicoletti F., Bruno V. Pharmacological activation of mGlu4 metabotropic glutamate receptors reduces nigrostriatal degeneration in mice treated with 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine. J. Neurosci. 2006, 26:7222-7229.
19. Baumann C.A., Mu L., Johannsen S., Honer M., Schubiger P.A., Ametamey S.M. Structure-activity relationships of fluorinated (E)-3-((6-Methylpyridin-2-yl)ethynyl)cyclohex-2-enone-O-methyloxime (ABP688) derivatives and the discovery of a high affinity analogue as a potential candidate for imaging metabotropic glutamate recepors subtype 5 (mGluR5) with positron emission tomography (PET). J. Med. Chem. 2010, 53:4009-4017.
20. Bear M.F., Dolen G., Osterweil E., Nagarajan N. Fragile X: translation in action. Neuropsychopharmacology 2008, 33:84-87.
21. Bellone C., Luscher C., Mameli M. Mechanisms of synaptic depression triggered by metabotropic glutamate receptors. Cell Mol. Life Sci. 2008, 65:2913-2923.
22. Benneyworth M.A., Xiang Z., Smith R.L., Garcia E.E., Conn P.J., Sanders-Bush E. A selective positive allosteric modulator of metabotropic glutamate receptor subtype 2 blocks a hallucinogenic drug model of psychosis. Mol. Pharmacol. 2007, 72:477-484.
23. Berry-Kravis E., Hessl D., Coffey S., Hervey C., Schneider A., Yuhas J., Hutchison J., Snape M., Tranfaglia M., Nguyen D.V., Hagerman R. A pilot open label, single dose trial of fenobam in adults with fragile X syndrome. J. Med. Genet. 2009, 46:266-271.
24. Bessis A.S., Bertrand H.O., Galvez T., De Colle C., Pin J.P., Acher F. Three-dimensional model of the extracellular domain of the type 4a metabotropic glutamate receptor: new insights into the activation process. Protein Sci. 2000, 9:2200-2209.
25. Bessis A.S., Rondard P., Gaven F., Brabet I., Triballeau N., Prezeau L., Acher F., Pin J.P. Closure of the Venus flytrap module of mGlu8 receptor and the activation process: Insights from mutations converting antagonists into agonists. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:11097-11102.
26. Beurrier C., Lopez S., Revy D., Selvam C., Goudet C., Lherondel M., Gubellini P., Kerkerian-LeGoff L., Acher F., Pin J.P. Electrophysiological and behavioral evidence that modulation of metabotropic glutamate receptor 4 with a new agonist reverses experimental parkinsonism. FASEB J. 2009, 23(10):3619-3628.
27. Bhave G., Nadin B.M., Brasier D.J., Glauner K.S., Shah R.D., Heinemann S.F., Karim F., Gereau R.W.T. Membrane topology of a metabotropic glutamate receptor. J. Biol. Chem. 2003, 278:30294-30301.
28. Black J.W., Leff P. Operational models of pharmacological agonism. Proc. R. Soc. Lond. B Biol. Sci. 1983, 220:141-162.
29. Brauner-Osborne H., Jensen A.A., Krogsgaard-Larsen P. Interaction of CPCCOEt with a chimeric mGlu1b and calcium sensing receptor. Neuroreport 1999, 10:3923-3925.
30. Campbell U.C., Lalwani K., Hernandez L., Kinney G.G., Conn P.J., Bristow L.J. The mGlu5 antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) potentiates PCP-induced cognitive deficits in rats. Psychopharmacology (Berl) 2004, 175:310-318.
31. Carroll F.Y., Stolle A., Beart P.M., Voerste A., Brabet I., Mauler F., Joly C., Antonicek H., Bockaert J., Muller T., Pin J.P., Prezeau L. BAY36-7620: a potent non-competitive mGlu1 receptor antagonist with inverse agonist activity. Mol. Pharmacol. 2001, 59:965-973.
32. Cartmell J., Monn J.A., Schoepp D.D. The metabotropic glutamate 2/3 receptor agonists LY354740 and LY379268 selectively attenuate phencyclidine versus d-amphetamine motor behaviors in rats. J. Pharmacol. Exp. Ther. 1999, 291:161-170.
33. Chen Y., Goudet C., Pin J.P., Conn P.J. N-{4-Chloro-2-[(1,3-dioxo-1,3-dihydro-2H-isoindol-2-yl)methyl]phenyl}-2-hy droxybenzamide (CPPHA) acts through a novel site as a positive allosteric modulator of group 1 metabotropic glutamate receptors. Mol. Pharmacol. 2008, 73:909-918.
34. Chen Y., Nong Y., Goudet C., Hemstapat K., de Paulis T., Pin J.P., Conn P.J. Interaction of novel positive allosteric modulators of metabotropic glutamate receptor 5 with the negative allosteric antagonist site is required for potentiation of receptor responses. Mol. Pharmacol. 2007, 71:1389-1398.
35. Cherezov V., Rosenbaum D.M., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., Choi H.J., Kuhn P., Weis W.I., Kobilka B.K., Stevens R.C. High-resolution crystal structure of an engineered human beta2-adrenergic G protein-coupled receptor. Science 2007, 318:1258-1265.
36. Chojnacka-Wojcik E., Tatarczynska E., Pilc A. The anxiolytic-like effect of metabotropic glutamate receptor antagonists after intrahippocampal injection in rats. Eur. J. Pharmacol. 1997, 319:153-156.
37. Conn P.J., Battaglia G., Marino M.J., Nicoletti F. Metabotropic glutamate receptors in the basal ganglia motor circuit. Nat. Rev. Neurosci. 2005, 6:787-798.
38. Conn P.J., Christopoulos A., Lindsley C.W. Allosteric modulators of GPCRs: a novel approach for the treatment of CNS disorders. Nat. Rev. Drug Discov. 2009, 8:41-54.
39. Conn P.J., Lindsley C.W., Jones C.K. Activation of metabotropic glutamate receptors as a novel approach for the treatment of schizophrenia. Trends Pharmacol. Sci. 2009, 30:25-31.
40. Conn P.J., Pin J.P. Pharmacology and functions of metabotropic glutamate receptors. Annu. Rev. Pharmacol. Toxicol. 1997, 37:205-237.
41. Conn P.J., Tamminga C., Schoepp D.D., Lindsley C. Schizophrenia: moving beyond monoamine antagonists. Mol. Interv. 2008, 8:99-107.
42. Cosford N.D., Tehrani L., Roppe J., Schweiger E., Smith N.D., Anderson J., Bristow L., Brodkin J., Jiang X., McDonald I., Rao S., Washburn M., Varney M.A. 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]-pyridine: a potent and highly selective metabotropic glutamate subtype 5 receptor antagonist with anxiolytic activity. J. Med. Chem. 2003, 46:204-206.
43. Cosford N.D., Roppe J., Tehrani L., Schweiger E.J., Seiders T.J., Chaudary A., Rao S., Varney M.A. [3H]-methoxymethyl-MTEP and [3H]-methoxy-PEPy: potent and selective radioligands for the metabotropic glutamate subtype 5 (mGlu5) receptor. Bioorg. Med. Chem. Lett. 2003, 13:351-354.
44. Coutinho V., Knopfel T. Metabotropic glutamate receptors: electrical and chemical signaling properties. Neuroscientist 2002, 8:551-561.
45. Crawford D.C., Acuna J.M., Sherman S.L. FMR1 and the fragile X syndrome: human genome epidemiology review. Genet. Med. 2001, 3:359-371.
46. Cube R.V., Vernier J.M., Hutchinson J.H., Gardner M.F., James J.K., Rowe B.A., Schaffhauser H., Daggett L., Pinkerton A.B. 3-(2-Ethoxy-4-{4-[3-hydroxy-2-methyl-4-(3-methylbutanoyl)phenoxy]butoxy} ph enyl)propanoic acid: a brain penetrant allosteric potentiator at the metabotropic glutamate receptor 2 (mGlu2). Bioorg. Med. Chem. Lett. 2005, 15:2389-2393.
47. Cuomo D., Martella G., Barabino E., Platania P., Vita D., Madeo G., Selvam C., Goudet C., Oueslati N., Pin J.P., Acher F., Pisani A., Beurrier C., Melon C., Kerkerian-Le Goff L., Gubellini P. Metabotropic glutamate receptor subtype 4 selectively modulates both glutamate and GABA transmission in the striatum: implications for Parkinson's disease treatment. J. Neurochem. 2009, 109:1096-1105.
48. de Paulis T., Hemstapat K., Chen Y., Zhang Y., Saleh S., Alagille D., Baldwin R.M., Tamagnan G.D., Conn P.J. Substituent effects of N-(1,3-diphenyl-1H-pyrazol-5-yl)benzamides on positive allosteric modulation of the metabotropic glutamate-5 receptor in rat cortical astrocytes. J. Med. Chem. 2006, 49:3332-3344.
49. Doherty A.J., Palmer M.J., Bortolotto Z.A., Hargreaves A., Kingston A.E., Ornstein P.L., Schoepp D.D., Lodge D., Collingridge G.L. A novel, competitive mGlu(5) receptor antagonist (LY344545) blocks DHPG-induced potentiation of NMDA responses but not the induction of LTP in rat hippocampal slices. Br. J. Pharmacol. 2000, 131:239-244.
50. Doherty J.J., Alagarsamy S., Bough K.J., Conn P.J., Dingledine R., Mott D.D. Metabotropic glutamate receptors modulate feedback inhibition in a developmentally regulated manner in rat dentate gyrus. J. Physiol. 2004, 561:395-401.
51. Dolen G., Osterweil E., Rao B.S., Smith G.B., Auerbach B.D., Chattarji S., Bear M.F. Correction of fragile X syndrome in mice. Neuron 2007, 56:955-962.
52. Dorr P., Westby M., Dobbs S., Griffin P., Irvine B., Macartney M., Mori J., Rickett G., Smith-Burchnell C., Napier C., Webster R., Armour D., Price D., Stammen B., Wood A., Perros M. Maraviroc (UK-427,857), a potent, orally bioavailable, and selective small-molecule inhibitor of chemokine receptor CCR5 with broad-spectrum anti-human immunodeficiency virus type 1 activity. Antimicrob. Agents Chemother. 2005, 49:4721-4732.
53. Ehlers M.D. Synapse structure: glutamate receptors connected by the shanks. Curr. Biol. 1999, 9:R848-R850.
54. Ehlert F.J. Estimation of the affinities of allosteric ligands using radioligand binding and pharmacological null methods. Mol. Pharmacol 1988, 33:187-194.
55. Eli Lilly A long-term, open-label, study on Schizophrenia. ClinicalTrials.gov [Internet] 2010, National Library of Medicine (US), Bethesda (MD), Available from:, NLM Identifier: NCT01129674, 2000 (cited 2010 Jun 23). http://clinicaltrials.gov/show/NCT01129674.
56. Ferraguti F., Shigemoto R. Metabotropic glutamate receptors. Cell Tissue Res. 2006, 326:483-504.
57. Friedmann C.T.H., Davis L.J., Ciccone P.E., Rubin R.T. Phase II double blind controlled study of a new anxiolytic, fenobam (McN-3377) vs placebo. Curr. Ther. Res. 1980, 27:144-151.
58. Flor P.J., Maj M., Dragic Z., Bruno V., Battaglia G., Inderbitzin W., van der Putten H., Kuhn R., Nicoletti F., Gasparini F. Positive allosteric modulators of metabotropic glutamate receptor subtype 4: pharmacological and molecular charaterization. Neuropharmacology 2002, 43:286.
59. Fukuda J., Suzuki G., Kimura T., Nagatomi Y., Ito S., Kawamoto H., Ozaki S., Ohta H. Identification of a novel transmembrane domain involved in the negative modulation of mGlu1 using a newly discovered allosteric mGlu1 antagonist, 3-cyclohexyl-5-fluoro-6-methyl-7-(2-morpholin-4-ylethoxy)-4H-chromen-4-one. Neuropharmacology 2009, 57:438-445.
60. Galandrin S., Oligny-Longpre G., Bouvier M. The evasive nature of drug efficacy: implications for drug discovery. Trends Pharmacol. Sci. 2007, 28:423-430.
61. Galici R., Echemendia N.G., Rodriguez A.L., Conn P.J. A selective allosteric potentiator of metabotropic glutamate (mGlu) 2 receptors has effects similar to an orthosteric mGlu2/3 receptor agonist in mouse models predictive of antipsychotic activity. J. Pharmacol. Exp. Ther. 2005, 315:1181-1187.
62. Galici R., Jones C.K., Hemstapat K., Nong Y., Echemendia N.G., Williams L.C., de Paulis T., Conn P.J. Biphenyl-indanone A, a positive allosteric modulator of the metabotropic glutamate receptor subtype 2, has antipsychotic- and anxiolytic-like effects in mice. J. Pharmacol. Exp. Ther. 2006, 318:173-185.
63. Garber K.B., Visootsak J., Warren S.T. Fragile X syndrome. Eur. J. Hum. Genet. 2008, 16:666-672.
64. Gaspar P.A., Bustamante M.L., Silva H., Aboitiz F. Molecular mechanisms underlying glutamatergic dysfunction in schizophrenia: therapeutic implications. J. Neurochem. 2009, 111:891-900.
65. Gasparini F., Andres H., Flor P.J., Heinrich M., Inderbitzin W., Lingenhohl K., Muller H., Munk V.C., Omilusik K., Stierlin C., Stoehr N., Vranesic I., Kuhn R. [(3)H]-M-MPEP, a potent, subtype-selective radioligand for the metabotropic glutamate receptor subtype 5. Bioorg. Med. Chem. Lett. 2002, 12:407-409.
66. Gasparini F., Floersheim P., Flor P.J., Heinrich M., Inderbitzin W., Ott D., Pagano A., Stierlin C., Stoehr N., Vranesic I., Kuhn R. Discovery and characterization of non-competitive antagonists of group I metabotropic glutamate receptors. Farmaco 2001, 56:95-99.
67. Gasparini F., Lingenhohl K., Stoehr N., Flor P.J., Heinrich M., Vranesic I., Biollaz M., Allgeier H., Heckendorn R., Urwyler S., Varney M.A., Johnson E.C., Hess S.D., Rao S.P., Sacaan A.I., Santori E.M., Velicelebi G., Kuhn R. 2-Methyl-6-(phenylethynyl)-pyridine (MPEP), a potent, selective and systemically active mGlu5 receptor antagonist. Neuropharmacology 1999, 38:1493-1503.
68. Gass J.T., Olive M.F. Positive allosteric modulation of mGlu5 receptors facilitates extinction of a cocaine contextual memory. Biol. Psychiatry 2009, 65:717-720.
69. Ginovart N., Wilson A.A., Hussey D., Houle S., Kapur S. D2-Receptor upregulation is dependent upon temporal course of D2-occupancy: a longitudinal [11C]-Raclopride PET study in cats. Neuropsychopharmacology 2009, 34:662-671.
70. Goldberg M.E., Salama A.I., Patel J.B., Malick J.B. Novel non-benzodiazepine anxiolytics. Neuropharmacology 1983, 22:1499-1504.
71. Goudet C., Gaven F., Kniazeff J., Vol C., Liu J., Cohen-Gonsaud M., Acher F., Prezeau L., Pin J.P. Heptahelical domain of metabotropic glutamate receptor 5 behaves like rhodopsin-like receptors. Proc. Natl. Acad. Sci. U.S.A. 2004, 101:378-383.
72. Govek S.P., Bonnefous C., Hutchinson J.H., Kamenecka T., McQuiston J., Pracitto R., Zhao L.X., Gardner M.F., James J.K., Daggett L.P., Rowe B.A., Schaffhauser H., Bristow L.J., Campbell U.C., Rodriguez D.E., Vernier J.M. Benzazoles as allosteric potentiators of metabotropic glutamate receptor 2 (mGlu2): efficacy in an animal model for schizophrenia. Bioorg. Med. Chem. Lett. 2005, 15:4068-4072.
73. Gravius A., Pietraszek M., Schäfer D., Schmidt W.J., Danysz W. Effects of mGlu1 and mGlu5 receptor antagonists on negatively reinforced learning. Behav. Pharmacol. 2005, 16(2):113-121.
74. Hall D.A. Modeling the functional effects of allosteric modulators at pharmacological receptors: an extension of the two-state model of receptor activation. Mol. Pharmacol. 2000, 58:1412-1423.
75. Hayashi Y., Sekiyama N., Nakanishi S., Jane D.E., Sunter D.C., Birse E.F., Udvarhelyi P.M., Watkins J.C. Analysis of agonist and antagonist activities of phenylglycine derivatives for different cloned metabotropic glutamate receptor subtypes. J. Neurosci. 1994, 14:3370-3377.
76. Hemstapat K., Da Costa H., Nong Y., Brady A.E., Luo Q., Niswender C.M., Tamagnan G.D., Conn P.J. A novel family of potent negative allosteric modulators of group II metabotropic glutamate receptors. J. Pharmacol. Exp. Ther. 2007, 322:254-264.
77. Hemstapat K., de Paulis T., Chen Y., Brady A.E., Grover V.K., Alagille D., Tamagnan G.D., Conn P.J. A novel class of positive allosteric modulators of metabotropic glutamate receptor subtype 1 interact with a site distinct from that of negative allosteric modulators. Mol. Pharmacol. 2006, 70:616-626.
78. Holst B., Frimurer T.M., Mokrosinski J., Halkjaer T., Cullberg K.B., Underwood C.R., Schwartz T.W. Overlapping binding site for the endogenous agonist, small-molecule agonists, and ago-allosteric modulators on the ghrelin receptor. Mol. Pharmacol. 2009, 75:44-59.
79. Huber K.M., Gallagher S.M., Warren S.T., Bear M.F. Altered synaptic plasticity in a mouse model of fragile X mental retardation. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:7746-7750.
80. Itil T.M., Seaman B.A., Huque M., Mukhopadhyay S., Blasucci D.N.K.T., Ciccone P.E. The clinical and quantitative EEG effects and plasma levels of fenobam (McN-3377) in subjects with anxiety: an open rising dose tolerance and efficacy study. Curr. Ther. Res. 1978, 708-724.
81. Jaakola V.P., Griffith M.T., Hanson M.A., Cherezov V., Chien E.Y., Lane J.R., Ijzerman A.P., Stevens R.C. The 2.6 angstrom crystal structure of a human A2A adenosine receptor bound to an antagonist. Science 2008, 322:1211-1217.
82. Johnson K.A., Conn P.J., Niswender C.M. Glutamate receptors as therapeutic targets for Parkinson's disease. CNS Neurol. Disord. Drug Targets 2009, 8:475-491.
83. Johnson M.P., Baez M., Jagdmann G.E., Britton T.C., Large T.H., Callagaro D.O., Tizzano J.P., Monn J.A., Schoepp D.D. Discovery of allosteric potentiators for the metabotropic glutamate 2 receptor: synthesis and subtype selectivity of N-(4-(2-methoxyphenoxy)phenyl)-N-(2,2,2- trifluoroethylsulfonyl)pyrid-3-ylmethylamine. J. Med. Chem. 2003, 46:3189-3192.
84. Johnson M.P., Barda D., Britton T.C., Emkey R., Hornback W.J., Jagdmann G.E., McKinzie D.L., Nisenbaum E.S., Tizzano J.P., Schoepp D.D. Metabotropic glutamate 2 receptor potentiators: receptor modulation, frequency-dependent synaptic activity, and efficacy in preclinical anxiety and psychosis model(s). Psychopharmacology (Berl) 2005, 179:271-283.
85. Jones C.K., Brady A.E., Davis A.A., Xiang Z., Bubser M., Tantawy M.N., Kane A.S., Bridges T.M., Kennedy J.P., Bradley S.R., Peterson T.E., Ansari M.S., Baldwin R.M., Kessler R.M., Deutch A.Y., Lah J.J., Levey A.I., Lindsley C.W., Conn P.J. Novel selective allosteric activator of the M1 muscarinic acetylcholine receptor regulates amyloid processing and produces antipsychotic-like activity in rats. J. Neurosci. 2008, 28:10422-10433.
86. Kenakin T. Functional selectivity through protean and biased agonism: who steers the ship?. Mol. Pharmacol. 2007, 72:1393-1401.
87. Keywood C., Wakefield M., Tack J. A proof-of-concept study evaluating the effect of ADX10059, a metabotropic glutamate receptor-5 negative allosteric modulator, on acid exposure and symptoms in gastro-oesophageal reflux disease. Gut 2009, 58(9):1192-1199.
88. Kinney G.G., O'Brien J.A., Lemaire W., Burno M., Bickel D.J., Clements M.K., Chen T.B., Wisnoski D.D., Lindsley C.W., Tiller P.R., Smith S., Jacobson M.A., Sur C., Duggan M.E., Pettibone D.J., Conn P.J., Williams D.L. A novel selective positive allosteric modulator of metabotropic glutamate receptor subtype 5 has in vivo activity and antipsychotic-like effects in rat behavioral models. J. Pharmacol. Exp. Ther. 2005, 313:199-206.
89. Knoflach F., Mutel V., Jolidon S., Kew J.N., Malherbe P., Vieira E., Wichmann J., Kemp J.A. Positive allosteric modulators of metabotropic glutamate 1 receptor: characterization, mechanism of action, and binding site. Proc. Natl. Acad. Sci. U.S.A. 2001, 98:13402-13407.
90. Kola I., Landis J. Can the pharmaceutical industry reduce attrition rates?. Nat. Rev. Drug Discov. 2004, 3:711-715.
91. Kratochwil N.A., Malherbe P., Lindemann L., Ebeling M., Hoener M.C., Muhlemann A., Porter R.H., Stahl M., Gerber P.R. An automated system for the analysis of G protein-coupled receptor transmembrane binding pockets: alignment, receptor-based pharmacophores, and their application. J. Chem. Inf. Model 2005, 45:1324-1336.
92. Krystal J.H., Abi-Saab W., Perry E., D'Souza D.C., Liu N., Gueorguieva R., McDougall L., Hunsberger T., Belger A., Levine L., Breier A. Preliminary evidence of attenuation of the disruptive effects of the NMDA glutamate receptor antagonist, ketamine, on working memory by pretreatment with the group II metabotropic glutamate receptor agonist, LY354740, in healthy human subjects. Psychopharmacology (Berl) 2005, 179:303-309.
93. Kunishima N., Shimada Y., Tsuji Y., Sato T., Yamamoto M., Kumasaka T., Nakanishi S., Jingami H., Morikawa K. Structural basis of glutamate recognition by a dimeric metabotropic glutamate receptor. Nature 2000, 407:971-977.
94. Langmead C.J., Fry V.A., Forbes I.T., Branch C.L., Christopoulos A., Wood M.D., Herdon H.J. Probing the molecular mechanism of interaction between 4-n-butyl-1-[4-(2-methylphenyl)-4-oxo-1-butyl]-piperidine (AC-42) and the muscarinic M(1) receptor: direct pharmacological evidence that AC-42 is an allosteric agonist. Mol. Pharmacol. 2006, 69:236-246.
95. Lavreysen H., Janssen C., Bischoff F., Langlois X., Leysen J.E., Lesage A.S. [3H]R214127: a novel high-affinity radioligand for the mGlu1 receptor reveals a common binding site shared by multiple allosteric antagonists. Mol. Pharmacol. 2003, 63:1082-1093.
96. Lazareno S., Dolezal V., Popham A., Birdsall N.J. Thiochrome enhances acetylcholine affinity at muscarinic M4 receptors: receptor subtype selectivity via cooperativity rather than affinity. Mol. Pharmacol. 2004, 65:257-266.
97. Leach K., Sexton P.M., Christopoulos A. Allosteric GPCR modulators: taking advantage of permissive receptor pharmacology. Trends Pharmacol. Sci. 2007, 28:382-389.
98. Lebois E.P., Bridges T.M., Lewis L.M., Dawson E.S., Kane A.S., Xiang Z., Jadhav S.B., Yin H., Kennedy J.P., Meiler J., Niswender C.M., Jones C.K., Conn P.J., Weaver C.D., Lindsley C. Discovery and characterization of novel subtype-selective allosteric agonists for the investigation of M1 receptor function in the central nervous system. ACS Chem. Neurosci. 2010, 1:104-121.
99. Lecourtier L., Homayoun H., Tamagnan G., Moghaddam B. Positive allosteric modulation of metabotropic glutamate 5 (mGlu5) receptors reverses N-Methyl-d-aspartate antagonist-induced alteration of neuronal firing in prefrontal cortex. Biol Psychiatry 2007, 62:739-746.
100. Lee H.G., Zhu X., O'Neill M.J., Webber K., Casadesus G., Marlatt M., Raina A.K., Perry G., Smith M.A. The role of metabotropic glutamate receptors in Alzheimer's disease. Acta Neurobiol. Exp. (Wars) 2004, 64:89-98.
101. Lee H.J., Mun H.C., Lewis N.C., Crouch M.F., Culverston E.L., Mason R.S., Conigrave A.D. Allosteric activation of the extracellular Ca2+-sensing receptor by l-amino acids enhances ERK1/2 phosphorylation. Biochem. J. 2007, 404:141-149.
102. Lindberg J.S., Culleton B., Wong G., Borah M.F., Clark R.V., Shapiro W.B., Roger S.D., Husserl F.E., Klassen P.S., Guo M.D., Albizem M.B., Coburn J.W. Cinacalcet HCl, an oral calcimimetic agent for the treatment of secondary hyperparathyroidism in hemodialysis and peritoneal dialysis: a randomized, double-blind, multicenter study. J. Am. Soc. Nephrol. 2005, 16:800-807.
103. Lindsley C.W., Wisnoski D.D., Leister W.H., O'Brien J.A., Lemaire W., Williams D.L., Burno M., Sur C., Kinney G.G., Pettibone D.J., Tiller P.R., Smith S., Duggan M.E., Hartman G.D., Conn P.J., Huff J.R. Discovery of positive allosteric modulators for the metabotropic glutamate receptor subtype 5 from a series of N-(1,3-diphenyl-1H- pyrazol-5-yl)benzamides that potentiate receptor function in vivo. J. Med. Chem. 2004, 47:5825-5828.
104. Lindsley C.W., Zhao Z., Leister W.H., O'Brien J., Lemaire W., Williams D.L., Chen T.B., Chang R.S., Burno M., Jacobson M.A., Sur C., Kinney G.G., Pettibone D.J., Tiller P.R., Smith S., Tsou N.N., Duggan M.E., Conn P.J., Hartman G.D. Design, synthesis, and in vivo efficacy of glycine transporter-1 (GlyT1) inhibitors derived from a series of [4-phenyl-1-(propylsulfonyl)piperidin-4-yl]methyl benzamides. Chem. Med. Chem. 2006, 1:807-811.
105. Litschig S., Gasparini F., Rueegg D., Stoehr N., Flor P.J., Vranesic I., Prezeau L., Pin J.P., Thomsen C., Kuhn R. CPCCOEt, a noncompetitive metabotropic glutamate receptor 1 antagonist, inhibits receptor signaling without affecting glutamate binding. Mol. Pharmacol. 1999, 55:453-461.
106. Liu F., Grauer S., Kelley C., Navarra R., Graf R., Zhang G., Atkinson P.J., Popiolek M., Wantuch C., Khawaja X., Smith D., Olsen M., Kouranova E., Lai M., Pruthi F., Pulicicchio C., Day M., Gilbert A., Pausch M.H., Brandon N.J., Beyer C.E., Comery T.A., Logue S., Rosenzweig-Lipson S., Marquis K.L. ADX47273 [S-(4-fluoro-phenyl)-{3-[3-(4-fluoro-phenyl)-[1,2,4]-oxadiazol-5-yl]-piper idin-1-yl}-methanone]: a novel metabotropic glutamate receptor 5-selective positive allosteric modulator with preclinical antipsychotic-like and procognitive activities. J. Pharmacol. Exp. Ther. 2008, 327:827-839.
107. Liu X., He Q., Studholme D.J., Wu Q., Liang S., Yu L. NCD3G: a novel nine-cysteine domain in family 3 GPCRs. Trends Biochem. Sci. 2004, 29:458-461.
108. Lorrain D.S., Schaffhauser H., Campbell U.C., Baccei C.S., Correa L.D., Rowe B., Rodriguez D.E., Anderson J.J., Varney M.A., Pinkerton A.B., Vernier J.M., Bristow L.J. Group II mGlu receptor activation suppresses norepinephrine release in the ventral hippocampus and locomotor responses to acute ketamine challenge. Neuropsychopharmacology 2003, 28:1622-1632.
109. Macek T.A., Winder D.G., Gereau R.W.T., Ladd C.O., Conn P.J. Differential involvement of group II and group III mGlus as autoreceptors at lateral and medial perforant path synapses. J. Neurophysiol. 1996, 76:3798-3806.
110. MacInnes N., Duty S. Group III metabotropic glutamate receptors act as hetero-receptors modulating evoked GABA release in the globus pallidus in vivo. Eur. J. Pharmacol. 2008, 580:95-99.
111. Maj M., Bruno V., Dragic Z., Yamamoto R., Battaglia G., Inderbitzin W., Stoehr N., Stein T., Gasparini F., Vranesic I., Kuhn R., Nicoletti F., Flor P.J. (-)-PHCCC, a positive allosteric modulator of mGlu4: characterization, mechanism of action, and neuroprotection. Neuropharmacology 2003, 45:895-906.
112. Malherbe P., Kratochwil N., Knoflach F., Zenner M.T., Kew J.N., Kratzeisen C., Maerki H.P., Adam G., Mutel V. Mutational analysis and molecular modeling of the allosteric binding site of a novel, selective, noncompetitive antagonist of the metabotropic glutamate 1 receptor. J. Biol. Chem. 2003, 278:8340-8347.
113. Malherbe P., Kratochwil N., Zenner M.T., Piussi J., Diener C., Kratzeisen C., Fischer C., Porter R.H. Mutational analysis and molecular modeling of the binding pocket of the metabotropic glutamate 5 receptor negative modulator 2-methyl-6-(phenylethynyl)-pyridine. Mol. Pharmacol. 2003, 64:823-832.
114. Malherbe P., Kratochwil N., Muhlemann A., Zenner M.-T., Fischer C., Stahl M., Gerber P.R., Jaeschke G., Porter R.H.P. Comparison of the binding pockets of two chemically unrelated allosteric antagonists of the mGlu5 receptor and identification of crucial residues involved in the inverse agonism of MPEP. J. Neurochem. 2006, 98:601-615.
115. Mannaioni G., Marino M.J., Valenti O., Traynelis S.F., Conn P.J. Metabotropic glutamate receptors 1 and 5 differentially regulate CA1 pyramidal cell function. J. Neurosci. 2001, 21:5925-5934.
116. Marino M.J., Conn P.J. Direct and indirect modulation of the N-methyl d-aspartate receptor. Curr. Drug Targets CNS Neurol. Disord. 2002, 1:1-16.
117. Marino M.J., Conn P.J. Glutamate-based therapeutic approaches: allosteric modulators of metabotropic glutamate receptors. Curr. Opin. Pharmacol. 2006, 6:98-102.
118. Marino M.J., Williams D.L., O'Brien J.A., Valenti O., McDonald T.P., Clements M.K., Wang R., DiLella A.G., Hess J.F., Kinney G.G., Conn P.J. Allosteric modulation of group III metabotropic glutamate receptor 4: a potential approach to Parkinson's disease treatment. Proc. Natl. Acad. Sci. U.S.A. 2003, 100:13668-13673.
119. Mathiesen J.M., Svendsen N., Brauner-Osborne H., Thomsen C., Ramirez M.T. Positive allosteric modulation of the human metabotropic glutamate receptor 4 (hmGlu4) by SIB-1893 and MPEP. Br. J. Pharmacol. 2003, 138:1026-1030.
120. Matsui T., Kita H. Activation of group III metabotropic glutamate receptors presynaptically reduces both GABAergic and glutamatergic transmission in the rat globus pallidus. Neuroscience 2003, 122:727-737.
121. May L.T., Avlani V.A., Langmead C.J., Herdon H.J., Wood M.D., Sexton P.M., Christopoulos A. Structure-function studies of allosteric agonism at M2 muscarinic acetylcholine receptors. Mol. Pharmacol. 2007, 72:463-476.
122. May L.T., Leach K., Sexton P.M., Christopoulos A. Allosteric modulation of g protein-coupled receptors. Annu. Rev. Pharmacol. Toxicol. 2007, 47:1-51.
123. Miedlich S.U., Gama L., Seuwen K., Wolf R.M., Breitwieser G.E. Homology modeling of the transmembrane domain of the human calcium sensing receptor and localization of an allosteric binding site. J. Biol. Chem. 2004, 279:7254-7263.
124. Mitsukawa K., Yamamoto R., Ofner S., Nozulak J., Pescott O., Lukic S., Stoehr N., Mombereau C., Kuhn R., McAllister K.H., van der Putten H., Cryan J.F., Flor P.J. A selective metabotropic glutamate receptor 7 agonist: activation of receptor signaling via an allosteric site modulates stress parameters in vivo. Proc. Natl. Acad. Sci. U.S.A. 2005, 102:18712-18717.
125. Moghaddam B., Adams B.W. Reversal of phencyclidine effects by a group II metabotropic glutamate receptor agonist in rats. Science 1998, 281:1349-1352.
126. Mohler H., Fritschy J.M., Rudolph U. A new benzodiazepine pharmacology. J. Pharmacol. Exp. Ther. 2002, 300:2-8.
127. Muhlemann A., Ward N.A., Kratochwil N., Diener C., Fischer C., Stucki A., Jaeschke G., Malherbe P., Porter R.H. Determination of key amino acids implicated in the actions of allosteric modulation by 3,3′-difluorobenzaldazine on rat mGlu5 receptors. Eur. J. Pharmacol. 2006, 529:95-104.
128. Muto T., Tsuchiya D., Morikawa K., Jingami H. Expression, purification, crystallization and preliminary X-ray analysis of the ligand-binding domain of metabotropic glutamate receptor 7. Acta Crystallogr. Sect. F Struct. Biol. Cryst. Commun. 2007, 63:627-630.
129. Natesan S., Reckless G.E., Nobrega J.N., Fletcher P.J., Kapur S. Dissociation between in vivo occupancy and functional antagonism of dopamine D2 receptors: comparing aripiprazole to other antipsychotics in animal models. Neuropsychopharmacology 2005, 31:1854-1863.
130. Nawaratne V., Leach K., Suratman N., Loiacono R.E., Felder C.C., Armbruster B.N., Roth B.L., Sexton P.M., Christopoulos A. New insights into the function of M4 muscarinic acetylcholine receptors gained using a novel allosteric modulator and a DREADD (designer receptor exclusively activated by a designer drug). Mol. Pharmacol. 2008, 74:1119-1131.
131. Nicholls R.E., Zhang X.L., Bailey C.P., Conklin B.R., Kandel E.R., Stanton P.K. mGlu2 acts through inhibitory Galpha subunits to regulate transmission and long-term plasticity at hippocampal mossy fiber-CA3 synapses. Proc. Natl. Acad. Sci. U.S.A. 2006, 103:6380-6385.
132. Niswender C.M., Conn P.J. Metabotropic glutamate receptors: physiology, pharmacology, and disease. Annu. Rev. Pharmacol. Toxicol. 2010, 50:295-322.
133. Niswender C.M., Johnson K.A., Miller N.R., Ayala J.E., Luo Q., Williams R., Saleh S., Orton D., Weaver C.D., Conn P.J. Context-dependent pharmacology exhibited by negative allosteric modulators of metabotropic glutamate receptor 7. Mol. Pharmacol. 2010, 77:459-468.
134. Niswender C.M., Johnson K.A., Weaver C.D., Jones C.K., Xiang Z., Luo Q., Rodriguez A.L., Marlo J.E., de Paulis T., Thompson A.D., Days E.L., Nalywajko T., Austin C.A., Williams M.B., Ayala J.E., Williams R., Lindsley C.W., Conn P.J. Discovery, characterization, and antiparkinsonian effect of novel positive allosteric modulators of metabotropic glutamate receptor 4. Mol. Pharmacol. 2008, 74:1345-1358.
135. Noeske T., Jirgensons A., Starchenkovs I., Renner S., Jaunzeme I., Trifanova D., Hechenberger M., Bauer T., Kauss V., Parsons C.G., Schneider G., Weil T. Virtual screening for selective allosteric mGlu1 antagonists and structure-activity relationship investigations for coumarine derivatives. Chem. Med. Chem. 2007, 2:1763-1773.
136. Noeske T., Trifanova D., Kauss V., Renner S., Parsons C.G., Schneider G., Weil T. Synergism of virtual screening and medicinal chemistry: identification and optimization of allosteric antagonists of metabotropic glutamate receptor 1. Bioorg. Med. Chem. 2009, 17:5708-5715.
137. Novartis Efficacy, safety and tolerability of AFQ056 in Fragile X Patients. ClinicalTrials.gov [Internet] 2010, National Library of Medicine (US), Bethesda (MD), Available from:, NLM Identifier: NCT00718341, 2000 (cited 2010 Jun 23). http://clinicaltrials.gov/ct2/show/NCT00718341.
138. Novartis Efficacy and safety of AFQ056 in reducing L-dopa induced dyskinesias in Parkinson's Disease patients, and safety in combination With L-dopa. ClinicalTrials.gov [Internet] 2010, National Library of Medicine (US), Bethesda (MD), Available from:, NLM Identifier: NCT00582673, 2000 (cited 2010 Jun 23). http://clinicaltrials.gov/show/NCT00582673.
139. Novartis Efficacy and Safety of AFQ056 in Reducing L-dopa Induced Dyskinesias in Parkinson's Disease Patients. ClinicalTrials.gov [Internet] 2010, National Library of Medicine (US), Bethesda (MD), Available from:, NLM Identifier: NCT00888004, 2000 (cited 2010 Jun 23). http://clinicaltrials.gov/show/NCT00888004.
140. Novartis Evaluation of the efficacy and safety of AFQ056 in reducing moderate to severe L-dopa induced dyskinesias in patients with Parkinson's disease. ClinicalTrials.gov [Internet] 2010, National Library of Medicine (US), Bethesda (MD), Available from:, NLM Identifier: NCT00986414, 2000 (cited 2010 Jun 23). http://clinicaltrials.gov/show/NCT00986414.
141. O'Brien J.A., Lemaire W., Chen T.B., Chang R.S., Jacobson M.A., Ha S.N., Lindsley C.W., Schaffhauser H.J., Sur C., Pettibone D.J., Conn P.J., Williams D.L. A family of highly selective allosteric modulators of the metabotropic glutamate receptor subtype 5. Mol. Pharmacol. 2003, 64:731-740.
142. O'Brien J.A., Lemaire W., Wittmann M., Jacobson M.A., Ha S.N., Wisnoski D.D., Lindsley C.W., Schaffhauser H.J., Rowe B., Sur C., Duggan M.E., Pettibone D.J., Conn P.J., Williams D.L. A novel selective allosteric modulator potentiates the activity of native metabotropic glutamate receptor subtype 5 in rat forebrain. J. Pharmacol. Exp. Ther. 2004, 309:568-577.
143. Ott D., Floersheim P., Inderbitzin W., Stoehr N., Francotte E., Lecis G., Richert P., Rihs G., Flor P.J., Kuhn R., Gasparini F. Chiral resolution, pharmacological characterization, and receptor docking of the noncompetitive mGlu1 receptor antagonist (+/-)-2-hydroxyimino- 1a, 2-dihydro-1H-7-oxacyclopropa[b]naphthalene-7a-carboxylic acid ethyl ester. J. Med. Chem. 2000, 43:4428-4436.
144. Pagano A., Ruegg D., Litschig S., Stoehr N., Stierlin C., Heinrich M., Floersheim P., Prezeau L., Carroll F., Pin J.P., Cambria A., Vranesic I., Flor P.J., Gasparini F., Kuhn R. The non-competitive antagonists 2-methyl-6-(phenylethynyl)pyridine and 7-hydroxyiminocyclopropan[b]chromen-1a-carboxylic acid ethyl ester interact with overlapping binding pockets in the transmembrane region of group I metabotropic glutamate receptors. J. Biol. Chem. 2000, 275:33750-33758.
145. Palczewski K., Kumasaka T., Hori T., Behnke C.A., Motoshima H., Fox B.A., Trong I.L., Teller D.C., Okada T., Stenkamp R.E., Yamamoto M., Miyano M. Crystal structure of rhodopsin: A G protein-coupled receptor. Science 2000, 289:739-745.
146. Palucha A., Pilc A. Metabotropic glutamate receptor ligands as possible anxiolytic and antidepressant drugs. Pharmacol. Ther. 2007, 115:116-147.
147. Parmentier M.L., Prezeau L., Bockaert J., Pin J.P. A model for the functioning of family 3 GPCRs. Trends Pharmacol. Sci. 2002, 23:268-274.
148. Patel J.B., Martin C., Malick J.B. Differential antagonism of the anticonflict effects of typical and atypical anxiolytics. Eur. J. Pharmacol. 1982, 86:295-298.
149. Patil S.T., Zhang L., Martenyi F., Lowe S.L., Jackson K.A., Andreev B.V., Avedisova A.S., Bardenstein L.M., Gurovich I.Y., Morozova M.A., Mosolov S.N., Neznanov N.G., Reznik A.M., Smulevich A.B., Tochilov V.A., Johnson B.G., Monn J.A., Schoepp D.D. Activation of mGlu2/3 receptors as a new approach to treat schizophrenia: a randomized Phase 2 clinical trial. Nat. Med. 2007, 13:1102-1107.
150. Pecknold J.C., McClure D.J., Appeltauer L., Wrzesinski L., Allan T. Treatment of anxiety using fenobam (a nonbenzodiazepine) in a double-blind standard (diazepam) placebo-controlled study. J. Clin. Psychopharmacol. 1982, 2:129-133.
151. Pelkey K.A., Yuan X., Lavezzari G., Roche K.W., McBain C.J. mGlu7 undergoes rapid internalization in response to activation by the allosteric agonist AMN082. Neuropharmacology 2007, 52:108-117.
152. Pietraszek M., Sukhanov I., Maciejak P., Szyndler J., Gravius A., Wisłowska A., Płaźnik A., Bespalov A.Y., Danysz W. Anxiolytic-like effects of mGlu1 and mGlu5 receptor antagonists in rats. Eur. J. Pharmacol. 2005, 514(1):25-34.
153. Pin J.P., Galvez T., Prezeau L. Evolution, structure, and activation mechanism of family 3/C G-protein-coupled receptors. Pharmacol. Ther. 2003, 98:325-354.
154. Pinheiro P.S., Mulle C. Presynaptic glutamate receptors: physiological functions and mechanisms of action. Nat. Rev. Neurosci. 2008, 9:423-436.
155. Pinkerton A.B., Cube R.V., Hutchinson J.H., James J.K., Gardner M.F., Rowe B.A., Schaffhauser H., Rodriguez D.E., Campbell U.C., Daggett L.P., Vernier J.M. Allosteric potentiators of the metabotropic glutamate receptor 2 (mGlu2). Part 3: Identification and biological activity of indanone containing mGlu2 receptor potentiators. Bioorg. Med. Chem. Lett. 2005, 15:1565-1571.
156. Pisani A., Gubellini P., Bonsi P., Conquet F., Picconi B., Centonze D., Bernardi G., Calabresi P. Metabotropic glutamate receptor 5 mediates the potentiation of N-methyl-d-aspartate responses in medium spiny striatal neurons. Neuroscience 2001, 106:579-587.
157. Poewe W.H., Lees A.J., Stern G.M. Low-dose L-dopa therapy in Parkinson's disease: a 6-year follow-up study. Neurology 1986, 36:1528-1530.
158. Poewe W.H., Lees A.J., Stern G.M. Treatment of motor fluctuations in Parkinson's disease with an oral sustained-release preparation of L-dopa: clinical and pharmacokinetic observations. Clin. Neuropharmacol. 1986, 9:430-439.
159. Poisik O., Raju D.V., Verreault M., Rodriguez A., Abeniyi O.A., Conn P.J., Smith Y. Metabotropic glutamate receptor 2 modulates excitatory synaptic transmission in the rat globus pallidus. Neuropharmacology 2005, 49(Suppl. 1):57-69.
160. Porter R.H., Jaeschke G., Spooren W., Ballard T.M., Buttelmann B., Kolczewski S., Peters J.U., Prinssen E., Wichmann J., Vieira E., Muhlemann A., Gatti S., Mutel V., Malherbe P. Fenobam: a clinically validated nonbenzodiazepine anxiolytic is a potent, selective, and noncompetitive mGlu5 receptor antagonist with inverse agonist activity. J. Pharmacol. Exp. Ther. 2005, 315:711-721.
161. Price M.R., Baillie G.L., Thomas A., Stevenson L.A., Easson M., Goodwin R., McLean A., McIntosh L., Goodwin G., Walker G., Westwood P., Marrs J., Thomson F., Cowley P., Christopoulos A., Pertwee R.G., Ross R.A. Allosteric modulation of the cannabinoid CB1 receptor. Mol. Pharmacol. 2005, 68:1484-1495.
162. Radestock S., Weil T., Renner S. Homology model-based virtual screening for GPCR ligands using docking and target-biased scoring. J. Chem. Inf. Model 2008, 48:1104-1117.
163. Rasmussen S.G., Choi H.J., Rosenbaum D.M., Kobilka T.S., Thian F.S., Edwards P.C., Burghammer M., Ratnala V.R., Sanishvili R., Fischetti R.F., Schertler G.F., Weis W.I., Kobilka B.K. Crystal structure of the human beta2 adrenergic G-protein-coupled receptor. Nature 2007, 450:383-387.
164. Rodrigues S.M., Bauer E.P., Farb C.R., Schafe G.E., LeDoux J.E. The group I metabotropic glutamate receptor mGlu5 is required for fear memory formation and long-term potentiation in the lateral amygdala. J. Neurosci. 2002, 22:5219-5229.
165. Rodriguez A.L., Nong Y., Sekaran N.K., Alagille D., Tamagnan G.D., Conn P.J. A close structural analog of 2-methyl-6-(phenylethynyl)-pyridine acts as a neutral allosteric site ligand on metabotropic glutamate receptor subtype 5 and blocks the effects of multiple allosteric modulators. Mol. Pharmacol. 2005, 68:1793-1802.
166. Romano C., Sesma M.A., McDonald C.T., O'Malley K., Van den Pol A.N., Olney J.W. Distribution of metabotropic glutamate receptor mGlu5 immunoreactivity in rat brain. J. Comp. Neurol. 1995, 355:455-469.
167. Romano C., Yang W.L., O'Malley K.L. Metabotropic glutamate receptor 5 is a disulfide-linked dimer. J. Biol. Chem. 1996, 271:28612-28616.
168. Rosenbaum D.M., Cherezov V., Hanson M.A., Rasmussen S.G., Thian F.S., Kobilka T.S., Choi H.J., Yao X.J., Weis W.I., Stevens R.C., Kobilka B.K. GPCR engineering yields high-resolution structural insights into beta2-adrenergic receptor function. Science 2007, 318:1266-1273.
169. Rondard P., Liu J., Huang S., Malhaire F., Vol C., Pinault A., Labesse G., Pin J.P. Coupling of agonist binding to effector domain activation in metabotropic glutamate-like receptors. J. Biol. Chem. 2006, 281:24653-24661.
170. Rowe B.A., Schaffhauser H., Morales S., Lubbers L.S., Bonnefous C., Kamenecka T.M., McQuiston J., Daggett L.P. Transposition of three amino acids transforms the human metabotropic glutamate receptor (mGlu)-3-positive allosteric modulation site to mGlu2, and additional characterization of the mGlu2-positive allosteric modulation site. J. Pharmacol. Exp. Ther. 2008, 326:240-251.
171. Rylander D., Iderberg H., Li Q., Dekundy A., Zhang J., Li H., Baishen R., Danysz W., Bezard E., Cenci M.A. A mGluR5 antagonist under clinical development improves L-DOPA-induced dyskinesia in parkinsonian rats and monkeys. Neurobiol. Dis 2010, 39:352-361.
172. Sachpatzidis A., Benton B.K., Manfredi J.P., Wang H., Hamilton A., Dohlman H.G., Lolis E. Identification of allosteric peptide agonists of CXCR4. J. Biol. Chem. 2003, 278:896-907.
173. Schaffhauser H., Rowe B.A., Morales S., Chavez-Noriega L.E., Yin R., Jachec C., Rao S.P., Bain G., Pinkerton A.B., Vernier J.M., Bristow L.J., Varney M.A., Daggett L.P. Pharmacological characterization and identification of amino acids involved in the positive modulation of metabotropic glutamate receptor subtype 2. Mol. Pharmacol. 2003, 64:798-810.
174. Schlumberger C., Pietraszek M., Gravius A., Danysz W. Effects of a positive allosteric modulator of mGlu5 ADX47273 on conditioned avoidance response and PCP-induced hyperlocomotion in the rat as models for schizophrenia. Pharmacol. Biochem. Behav. 2010, 95:23-30.
175. Schlumberger C., Pietraszek M., Gravius A., Klein K.U., Greco S., More L., Danysz W. Comparison of the mGlu(5) receptor positive allosteric modulator ADX47273 and the mGlu(2/3) receptor agonist LY354740 in tests for antipsychotic-like activity. Eur. J. Pharmacol. 2009, 623:73-83.
176. Schoepp, D.D., 2004. Case Study: utility of metabotropic glutamate agonists in psychiatric illness. 5th World Conference on Stress, Abs 120.
177. Schoepp D.D., Wright R.A., Levine L.R., Gaydos B., Potter W.Z. LY354740, an mGlu2/3 receptor agonist as a novel approach to treat anxiety/stress. Stress 2003, 6:189-197.
178. Schulz B., Fendt M., Gasparini F., Lingenhohl K., Kuhn R., Koch M. The metabotropic glutamate receptor antagonist 2-methyl-6-(phenylethynyl)-pyridine (MPEP) blocks fear conditioning in rats. Neuropharmacology 2001, 41:1-7.
179. Schwartz T.W., Holst B. Allosteric enhancers, allosteric agonists and ago-allosteric modulators: where do they bind and how do they act?. Trends Pharmacol. Sci. 2007, 28:366-373.
180. Slassi A., Isaac M., Edwards L., Minidis A., Wensbo D., Mattsson J., Nilsson K., Raboisson P., McLeod D., Stormann T.M., Hammerland L.G., Johnson E. Recent advances in non-competitive mGlu5 receptor antagonists and their potential therapeutic applications. Curr. Top. Med. Chem. 2005, 5:897-911.
181. Spalding T.A., Ma J.N., Ott T.R., Friberg M., Bajpai A., Bradley S.R., Davis R.E., Brann M.R., Burstein E.S. Structural requirements of transmembrane domain 3 for activation by the M1 muscarinic receptor agonists AC-42, AC-260584, clozapine, and N-desmethylclozapine: evidence for three distinct modes of receptor activation. Mol. Pharmacol. 2006, 70:1974-1983.
182. Spalding T.A., Trotter C., Skjaerbaek N., Messier T.L., Currier E.A., Burstein E.S., Li D., Hacksell U., Brann M.R. Discovery of an ectopic activation site on the M(1) muscarinic receptor. Mol. Pharmacol. 2002, 61:1297-1302.
183. Spooren W., Gasparini F. mGlu5 receptor antagonists: a novel class of anxiolytics?. Drug News Perspect. 2004, 17:251-257.
184. Spooren W.P., Schoeffter P., Gasparini F., Kuhn R., Gentsch C. Pharmacological and endocrinological characterisation of stress-induced hyperthermia in singly housed mice using classical and candidate anxiolytics (LY314582, MPEP and NKP608). Eur. J. Pharmacol. 2002, 435:161-170.
185. Spooren W.P., Vassout A., Neijt H.C., Kuhn R., Gasparini F., Roux S., Porsolt R.D., Gentsch C. Anxiolytic-like effects of the prototypical metabotropic glutamate receptor 5 antagonist 2-methyl-6-(phenylethynyl)pyridine in rodents. J. Pharmacol. Exp. Ther. 2000, 295:1267-1275.
186. Steckler T., Lavreysen H., Oliveira A.M., Aerts N., Craenendonck H., Prickaerts J., Megens A., Lesage A.S. Effects of mGlu1 receptor blockade on anxiety-related behaviour in the rat lick suppression test. Psychopharmacology 2005, 179:198-206.
187. Steckler T., Oliveira A.F., Van Dyck C., Van Craenendonck H., Mateus A.M., Langlois X., Lesage A.S., Prickaerts J. Metabotropic glutamate receptor 1 blockade impairs acquisition and retention in a spatial Water maze task. Behav. Brain Res. 2005, 164:52-60.
188. Stefani M.R., Moghaddam B. Activation of type 5 metabotropic glutamate receptors attenuates deficits in cognitive flexibility induced by NMDA receptor blockade. Eur. J. Pharmacol. 2010, 639:26-32.
189. Stockton J.M., Birdsall N.J., Burgen A.S., Hulme E.C. Modification of the binding properties of muscarinic receptors by gallamine. Mol. Pharmacol 1983, 23:551-557.
190. Surin A., Pshenichkin S., Grajkowska E., Surina E., Wroblewski J.T. Cyclothiazide selectively inhibits mGlu1 receptors interacting with a common allosteric site for non-competitive antagonists. Neuropharmacology 2007, 52:744-754.
191. Suzuki G., Kimura T., Satow A., Kaneko N., Fukuda J., Hikichi H., Sakai N., Maehara S., Kawagoe-Takaki H., Hata M., Azuma T., Ito S., Kawamoto H., Ohta H. Pharmacological characterization of a new, orally active and potent allosteric metabotropic glutamate receptor 1 antagonist, 4-[1-(2-fluoropyridin-3-yl)-5-methyl-1H-1,2,3-triazol-4-yl]-N-isopropyl-N- methyl-3,6-dihydropyridine-1(2H)-carboxamide (FTIDC). J. Pharmacol. Exp. Ther. 2007, 321:1144-1153.
192. Swanson C.J., Bures M., Johnson M.P., Linden A.M., Monn J.A., Schoepp D.D. Metabotropic glutamate receptors as novel targets for anxiety and stress disorders. Nat. Rev. Drug Discov. 2005, 4:131-144.
193. Takahashi K., Tsuchida K., Tanabe Y., Masu M., Nakanishi S. Role of the large extracellular domain of metabotropic glutamate receptors in agonist selectivity determination. J. Biol. Chem. 1993, 268:19341-19345.
194. Tatarczynska E., Klodzinska A., Kroczka B., Chojnacka-Wojcik E., Pilc A. The antianxiety-like effects of antagonists of group I and agonists of group II and III metabotropic glutamate receptors after intrahippocampal administration. Psychopharmacology (Berl) 2001, 158:94-99.
195. Teller D.C., Okada T., Behnke C.A., Palczewski K., Stenkamp R.E. Advances in determination of a high-resolution three-dimensional structure of rhodopsin, a model of G-protein-coupled receptors (GPCRs). Biochemistry 2001, 40:7761-7772.
196. Tones M.A., Bendali N., Flor P.J., Knopfel T., Kuhn R. The agonist selectivity of a class III metabotropic glutamate receptor, human mGlu4a, is determined by the N-terminal extracellular domain. Neuroreport 1995, 7:117-120.
197. Treyer V., Streffer J., Ametamey S.M., Bettio A., Bläuenstein P., Schmidt M., Gasparini F., Hock C., Buck A. Radiation dosimetry and biodistribution of 11C-ABP688 measured in healthy volunteers. Eur. J. Nucl. Med. Mol. Imaging 2008, 35(4):766-770.
198. Tsuchiya D., Kunishima N., Kamiya N., Jingami H., Morikawa K. Structural views of the ligand-binding cores of a metabotropic glutamate receptor complexed with an antagonist and both glutamate and Gd3+. Proc. Natl. Acad. Sci. U.S.A. 2002, 99:2660-2665.
199. Tu H., Rondard P., Xu C., Bertaso F., Cao F., Zhang X., Pin J.P., Liu J. Dominant role of GABAB2 and Gbetagamma for GABAB receptor-mediated-ERK1/2/CREB pathway in cerebellar neurons. Cell Signal 2007, 19:1996-2002.
200. Ugolini A., Corsi M., Bordi F. Potentiation of NMDA and AMPA responses by the specific mGlu5 agonist CHPG in spinal cord motoneurons. Neuropharmacology 1999, 38:1569-1576.
201. Urban J.D., Clarke W.P., von Zastrow M., Nichols D.E., Kobilka B., Weinstein H., Javitch J.A., Roth B.L., Christopoulos A., Sexton P.M., Miller K.J., Spedding M., Mailman R.B. Functional selectivity and classical concepts of quantitative pharmacology. J. Pharmacol. Exp. Ther. 2007, 320:1-13.
202. Ure J., Baudry M., Perassolo M. Metabotropic glutamate receptors and epilepsy. J. Neurol. Sci. 2006, 247:1-9.
203. Uslaner J.M., Parmentier-Batteur S., Flick R.B., Surles N.O., Lam J.S., McNaughton C.H., Jacobson M.A., Hutson P.H. Dose-dependent effect of CDPPB, the mGlu5 positive allosteric modulator, on recognition memory is associated with GluR1 and CREB phosphorylation in the prefrontal cortex and hippocampus. Neuropharmacology 2009, 57:531-538.
204. Valant C., Gregory K.J., Hall N.E., Scammells P.J., Lew M.J., Sexton P.M., Christopoulos A. A novel mechanism of G protein-coupled receptor functional selectivity. Muscarinic partial agonist McN-A-343 as a bitopic orthosteric/allosteric ligand. J. Biol. Chem. 2008, 283:29312-29321.
205. Valenti O., Conn P.J., Marino M.J. Distinct physiological roles of the Gq-coupled metabotropic glutamate receptors Co-expressed in the same neuronal populations. J. Cell Physiol. 2002, 191:125-137.
206. Valenti O., Mannaioni G., Seabrook G.R., Conn P.J., Marino M.J. Group III metabotropic glutamate-receptor-mediated modulation of excitatory transmission in rodent substantia nigra pars compacta dopamine neurons. J. Pharmacol. Exp. Ther. 2005, 313:1296-1304.
207. Valenti O., Marino M.J., Wittmann M., Lis E., DiLella A.G., Kinney G.G., Conn P.J. Group III metabotropic glutamate receptor-mediated modulation of the striatopallidal synapse. J. Neurosci. 2003, 23:7218-7226.
208. Vanejevs M., Jatzke C., Renner S., Muller S., Hechenberger M., Bauer T., Klochkova A., Pyatkin I., Kazyulkin D., Aksenova E., Shulepin S., Timonina O., Haasis A., Gutcaits A., Parsons C.G., Kauss V., Weil T. Positive and negative modulation of group I metabotropic glutamate receptors. J. Med. Chem. 2008, 51:634-647.
209. Varney M.A., Cosford N.D., Jachec C., Rao S.P., Sacaan A., Lin F.F., Bleicher L., Santori E.M., Flor P.J., Allgeier H., Gasparini F., Kuhn R., Hess S.D., Velicelebi G., Johnson E.C. SIB-1757 and SIB-1893: selective, noncompetitive antagonists of metabotropic glutamate receptor type 5. J. Pharmacol. Exp. Ther. 1999, 290:170-181.
210. Wadenberg M.L., Soliman A., VanderSpek S.C., Kapur S. Dopamine D(2) receptor occupancy is a common mechanism underlying animal models of antipsychotics and their clinical effects. Neuropsychopharmacology 2001, 25:633-641.
211. Wichmann T., DeLong M.R. Functional neuroanatomy of the basal ganglia in Parkinson's disease. Adv. Neurol. 2003, 91:9-18.
212. Yan Q.J., Rammal M., Tranfaglia M., Bauchwitz R.P. Suppression of two major Fragile X Syndrome mouse model phenotypes by the mGlu5 antagonist MPEP. Neuropharmacology 2005, 49:1053-1066.
213. Yarnitzky T., Levit A., Niv M.Y. Homology modeling of G-protein-coupled receptors with X-ray structures on the rise. Curr. Opin. Drug Discov. Devel. 2010, 13(3):317-325.
214. Yu M. Recent developments of the PET imaging agents for metabotropic glutamate receptor subtype 5. Curr. Top. Med. Chem. 2007, 7:1800-1805.
215. Zerbib, F., Keywood, C., Strabach, G., 2010. Efficacy, tolerability and pharmacokinetics of a modified release formulation of ADX10059, a negative allosteric modulator of metabotropic glutamate receptor 5: an esophageal pH-impedance study in healthy subjects. Neurogastroenterol. Motil. 22, 859-e231.
216. Zhang Y., Rodriguez A.L., Conn P.J. Allosteric potentiators of metabotropic glutamate receptor subtype 5 have differential effects on different signaling pathways in cortical astrocytes. J. Pharmacol. Exp. Ther. 2005, 315:1212-1219.
217. Zhao Z., Wisnoski D.D., O'Brien J.A., Lemaire W., Williams D.L., Jacobson M.A., Wittman M., Ha S.N., Schaffhauser H., Sur C., Pettibone D.J., Duggan M.E., Conn P.J., Hartman G.D., Lindsley C.W. Challenges in the development of mGlu5 positive allosteric modulators: the discovery of CPPHA. Bioorg. Med. Chem. Lett. 2007, 17:1386-1391.